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Abstract
Chemokine-like factor 1 (CKLF1) is a novel cytokine first cloned from U937 cells. It contains different splicing forms and has chemotactic
effects on a wide spectrum of cells both in vitro and in vivo; it can also stimulate the regeneration of skeletal muscle cells in vivo, but the
mechanism remains unclear. To probe the myogenesis function of CKLF2, which is the largest isoform of CKLFs, C2C12 murine myoblasts
were stably transfected with human CKLF2 eukaryotic expression vector. Compared with control vector transfected C2C12 cells, CKLF2
overexpression causes accelerated myoblast proliferation as determined by cell counting and [3H]TdR incorporation assays. In addition,
CKLF2 overexpression also promotes cell differentiation, which was determined by higher expression levels of myogenin, creatine kinase,
myosin and the accelerated myoblast fusion. Further analysis also indicates that CKLF2 could activate the transcription activity of the bHLH/
MyoD and MEF2 families. Finally, DNA synthesis and myotube formation could also be promoted by growing C2C12 cells in conditioned
media from CKLF2-transfected cells. These findings strongly suggest a role for human CKLF2 in regulation of skeletal muscle myogenesis.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Chemokine-like factor 1 (CKLF1) is a novel cytokine
isolated in our laboratory, which has at least three isoforms,
CKLF2, CKLF3 and CKLF4, of which CKLF2 is the full-
length cDNA product. Our previous studies showed that
CKLF1 could attract monocytes, lymphocytes and neutro-
phils both in vitro and in vivo and stimulate the regeneration
of skeletal muscle cells in vivo. The enhancing effect on
satellite cells may be caused directly by CKLF1 or the
cytokines secreted by the attracted leukocytes [1].
Satellite cells are small mononuclear cells first identified
by Mauro [2] lying under the basal lamina of the myofiber.
These cells are present in muscle mostly in their quiescent
state. Nevertheless, upon muscle injury, satellite cells
become mitotically active, displaying programmed prolifer-
ation and differentiation followed by expression of muscle-
specific proteins [3,4].
The extracellular factors that activate quiescent satellite
cells and regulate their proliferation and differentiation
processes during muscle growth and regeneration have not
been completely elucidated. Nevertheless, several growth
factors have been implicated in stimulating or inhibiting
satellite cell growth. Growth factors such as fibroblast
growth factor (FGF) or hepatocyte growth factor (HGF)
promote the proliferation but inhibit the differentiation of
muscle cells, with the exception of insulin-like growth
factor 1 (IGF-1), which displays promoting activity on both
proliferation and differentiation of muscle cells [5–8].
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Molecular mechanisms controlling myogenesis at the
transcriptional level have been well characterized. The
differentiation of skeletal muscle cells involves the expres-
sion and activation of two major transcription factors: basic
helix–loop–helix (bHLH) family and myocyte enhancer
factor 2 (MEF2) family. The bHLH family contains MyoD,
Myf5, myogenin and myogenic regulatory factor-4 (MRF4)
[9], while MyoD and Myf-5 are expressed in the myoblast
cells prior to the onset of muscle differentiation [9–12];
once activated, MyoD and Myf5 induce the expression of
myogenin and MRF4, as well as the other important tran-
scription factors of the MEF2 family.
MEF2 cooperates with bHLH family members in the
activation of many muscle structural genes [13,14]. Mem-
bers of the MEF-2 family of transcription factors play a
critical role in the activation of contractile protein tran-
scription. The MEF-2 family is encoded by four independ-
ent genes, MEF2A, MEF2B, MEF2C and MEF2D [14].
MEF-2 proteins and DNA-bound bHLH factors synergisti-
cally regulate transcription by cooperative mechanisms that
involve direct physical association [15]. In mammalian
animals, MEF2A, MEF2B and MEF2D are ubiquitously
expressed, whereas MEF2C is restricted to skeletal muscle
and brain, MEF2C DNA-binding activity is highly enriched
in muscle and neural tissue.
In this study, we transfected C2C12, a mouse satellite cell
line, with human CKLF2 expression vector to analyze the
effects and possible mechanisms of CKLF activity on the
proliferation and differentiation of muscle cells. This cell
line was selected since it is a pure, immortalized mouse
satellite cell line, which is morphologically similar to
primary satellite cell cultures [16–18]. Moreover, unlike
other muscle cell lines, e.g. L6 cells, C2C12 cells have an
unrestricted profile of myogenic factor expression, including
Myf-5, myogenin, MRF-4 and MyoD. Here, we demon-
strate that overexpression of CKLF2 in C2C12 accelerates
transcription of several muscle-specific genes, myosin light-
chain 2 (MLC2) and muscle creatine kinase (MCK), both in
the serum-rich and low-level serum medium. The study also
indicates that expression of CKLF2 enhances cell prolifer-
ation. The in vitro transfection assays provide evidences that
the muscle-stimulating effect of CKLF2 is independent of
other cytokines. Therefore, CKLF2 may directly participate
in the regeneration of muscle cells.
2. Materials and methods
2.1. Materials
The C2C12 cell line was purchased from ATCC. The
plasmid of pcDNA3.1/Myc-HisB( ) was obtained from
Invitrogen Life Technologies (Carlsbad, CA). The luciferase
reporter plasmid of pGL3-Basic and the Luciferase assay
system was from Promega (Madison, WI). A SUPER-
SCRIPTk first-Strand Synthesis System for RT-PCR, Tri-
zol, Dulbecco modified Eagle medium (DMEM), horse
serum (HS) and G418 were obtained from Invitrogen Life
Technologies. Anti-mouse myogenin monoclonal antibody
(F5D) from BD Biosciences Pharmingen (San Diego, CA)
was used. Anti-Myosin heavy chain (MF20) was from
DSHB (The University of Iowa, Iowa City, IA). Fetal calf
serum was purchased from Hyclone (Logan, UT). fluores-
cein isothiocyanate (FITC)–phalloidin and creatine phos-
phokinase assay kits were provided by Sigma-Aldrich Corp.
(St. Louis, MO). SYBR Green PCR Core Reagent for real-
time PCR was gotten from Applied Biosystems (Foster City,
CA).
2.2. Plasmids
To construct the eukaryotic expression vector, the frag-
ment containing the complete CKLF2 ORF was released
from the recombinant plasmid pGEM-T–CKLF2 [1] by
cutting with EcoRI and subcloned into the EcoRI site of
pcDNA3.1. The sense pcDNA3.1–CKLF2 was selected by
restriction enzyme analysis and the CKLF2 insert was
confirmed by DNA sequencing.
The reporter plasmid of pGL3 myogenin containing
myogenin promoter was constructed according to the paper
described by Yee and Rigby [19]. 4RE-tK-Luc that contains
four copies of E-box and 3MEF2-tK-Luc that contains
three copies of MEF2 binding sites were kindly provided by
Dr. Zhenguo Wu [20] and have been described elsewhere
[21,22].
2.3. Cell culture
Mouse myoblast cell line C2C12 was maintained as
subconfluent monolayers in DMEM containing 4.5 g/l
glucose and 4 mM L-glutamine supplemented with 15%
fetal bovine serum (FBS), 100 U/ml penicillin and 100 Ag/
ml streptomycin. To induce differentiation, the medium was
changed to DMEM supplemented with 1% horse donor
serum. During cell differentiation, the medium was changed
every day.
2.4. Stable transfection and isolation of clones
C2C12 cells were plated at 12,000 cells/60-mm-diameter
tissue culture dish a day before cells were transfected with 5
Ag plasmid DNA by calcium phosphate precipitation pro-
cedure [23]. Two days later, cells were washed and plated
onto a 100-mm diameter dish in growth medium (GM)
containing 400 Ag/ml of G418. Selection proceeded for 2
weeks; the medium was changed every 3 days. The G418-
resistant clones were harvested and analyzed.
2.5. Cell proliferation assay
Cells were plated in six-well plates (8000 cells/well) and
cultured continuously for 5 days. Cells were detached from
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the plate with 0.25% trypsin–EDTA and then resuspended
in PBS with 0.4% trypan blue. Viable cells as determined by
trypan blue exclusion were counted using a hemocytometer
[24]. Plating efficiency was controlled to avoid significant
variation among groups in this experimental protocol.
2.5.1. Thymidine incorporation
DNA synthesis was assessed by [3H]thymidine incorpo-
ration. Cells were plated onto a 96-well plate 24 h before
[3H]thymidine was added (1 ACi/ml) for an additional 6 h
incubation. Cells were harvested by TOMTEC Harvester
96R onto a 96-well Filtermat (Perkin Elmer, Torrance, CA).
The incorporation of [3H]thymidine was determined by
MicroBeta Windows Workstation (Perkin Elmer).
2.6. Cell cycle analysis
When C2C12/CKLF2 and C2C12/Vector cells reached
70–80% confluence, they were washed with PBS, detached
with 0.25% trypsin–EDTA and fixed with 75% ethanol
overnight. Samples were washed and resuspended in 0.5 ml
PBS and RNAwas eliminated by digestion with RNaseA for
30 min. Before the DNA contents were measured by
fluorescence-activated cell sorting (FACS) on a Becton-
Dickinson FACScan flow cytometry system, cells were
stained with propidium iodide (PI) in the dark for 30 min.
The data were analyzed using CellFIT software.
2.7. RNA isolation and quantitative real-time RT-PCR
Total RNA was isolated from cell cultures using Trizol
reagent. Reverse transcription (RT) was performed using a
SUPERSCRIPTk first-Strand Synthesis System according
to the user manual. Quantitative real-time PCR assay was
carried out in an ABI PRISM 7700 Sequence Detection
System (Applied Biosystems) to assess expression of MLC2
and MCK. PCR reactions were performed according to the
user manual. Preliminary reactions were run to optimize the
concentration and ratio of each primer set. The purpose of
this procedure is to determine the minimum primer concen-
trations giving the maximum DRn and minimum nonspecific
amplification. The pure DNA probe of interest was used as
template to generate a standard curve. The 7700 program
consisted of one AmpErase UNG incubation (50 jC, held 2
min), followed by 95 jC for 10 min to activate AmpliTaq
Gold and inactivate AmpErase UNG, then 40 cycles of 95
jC for 15 s, then 60 jC for 1 min. Each pair of primers have
2 jC or less difference in Tm and generate a product around
the optimal range (500 bp) for SYBR Green I dye quanti-
fication. The sequences of the primers used are listed in
Table 1. 18S rRNA was included as the internal control for
each cDNA sample.
2.8. Cell labeling with phalloidin
In order to observe the formation of myotubes in differ-
entiated cells, filament actin was stained with FITC–phal-
loidin. Immunofluorescence was carried out as described by
Chen et al. [25]. Briefly, at indicated days of differentiation,
cells cultured on a 24-well plate were rinsed with cold PBS
(PH7.4) and fixed with 2% paraformaldehyde and 0.1%
Triton X100, then the cells were rinsed again and stained
with FITC–phalloidin (Sigma) at 200 ng/ml at room tem-
perature for 30 min. Hoechst 33258 nuclear dye was added
with FITC–phalloidin at a final concentration of 500 ng/ml.
Fluorescent images were captured on an Olympus fluores-
cent microscope with a coupled charged device (CCD)
camera.
2.9. Creatine kinase assay
Muscle creatine kinase activity assay was performed
according to the manual provided with a Sigma Creatine
Phosphokinase assay kit. The procedure was adapted to a
96-well microplate assay. Briefly, deionized water was
added to each vial to dissolve the NADH-containing sub-
strate, cell extract was added, mixed and absorbance at 340
nm was measured every minute. For each well, 300 Al of
substrate and 10 Al of cell extract were added. The OD 340
nm absorbance was measured on a POLARstar galaxy
(BMG Labtechnologies Pty. Ltd., Mornington, Victoria,
Australia) spectrometer. In each test, cell extracts were
quantified and normalized to equal concentration.
2.10. Western blot analysis
Nuclear proteins were extracted from myoblasts and
myotubes as previously described [26]. Protein concentra-
tion was determined using a Coomassie Plus Protein Assay
Reagent Kit (Pierce Chemical Corp., Rockford, IL). Proteins
were separated on SDS-PAGE and transferred to Hybond-
ECL membranes (Amersham Biosciences, Inc., Piscataway,
NJ). The membranes were reacted with primary antibodies
and then HRP-conjugated anti-mouse IgG (Promega). Pro-
teins were detected by ECL Western Blotting Detection
Reagent (Pierce).
Table 1
PCR primers used for real-time PCR analysis
Forward Reverse
18S RNA 5V-TCG AAC GTC TGC CCT ATC AA-3V 5V-GCT ATT GGA GCT GGA ATT ACC G-3V
MLC2 5V-ATG GCA CCC AAG AAG GCC AA-3V 5V-CTA TTC CTG GTC CTT AGC ATC-3V
MCK 5V-ACC TGG ACC CCA ACT ATG TG-3V 5V-ATC ATG TCG TCG ATG GAC TG-3V
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2.11. DNA transient transfection and luciferase assays
C2C12 cells were seeded at 1.5 105 cells/well onto six-
well plates in triplicates. On the following day, cells were
transfected with various reporter plasmids, as indicated in
the figures. Two hundred nanograms of the pEGFP-N1
plasmid (BD Biosciences Clontech, Palo Alto, CA) were
included in transfections as an internal control for trans-
fection efficiency. Luciferase activities were determined in
aliquots of cell extracts from harvested cells 48 h after
transfection in GM and 24 h after being switched to differ-
entiation medium (DM). Luciferase activity was assayed
using a Luciferase Assay System (Promega) according to
the manufacturer’s instructions. All luciferase activities
were determined and designated as relative luminescence
units (RLU) by POLARstar galaxy spectrometer. The
results were normalized with equivalent quantities of GFP
proteins.
2.12. Paracrine effects of CKLF2
In addition to the above studies, we also probed the
paracrine effects of CKLF2 as described [27], we seeded
wild C2C12 cells in a 96-well plate, and cultured them in
75% CKLF2-conditioned medium and control conditioned
medium. After 48 h, cell proliferation was evaluated by
[3H]TdR incorporation.
For the cell differentiation assay, CKLF2-conditioned
medium were added at the proliferation stage, and switched
to CKLF2-conditioned DM when cells reached 80% con-
fluence. Medium was changed every 24 h. Forty-eight hours
later, myotubes were observed and images were captured
with a CCD camera.
2.13. Statistical analysis
The S.D. (standard deviation) in results are presented as
means of multiple (three to six) replicate cultures within
each treatment group and results are presented for a single
representative experiment. Observations were confirmed in
at least three independent experiments using different cell
preparations. Student’s t-test was employed to assess the
significance of differences between different treatment
groups. Statistical significance was set at P < 0.05.
3. Results
3.1. Generation of C2C12 myoblast cell lines
overexpressing CKLF2
To study how CKLF2 affects the proliferation and differ-
entiation of myoblasts, we generated C2C12 cell lines
expressing CKLF2 and a control C2C12 cell line containing
the pcDNA3.1 vector. Cells were drug-selected and survival
clones were collected. Four G418 resistant clones were
randomly selected and analyzed for the expression level of
CKLF2 by semiquantitative RT-PCR. CKLF2 mRNA
expression differed somewhat between several different
CKLF2 positive clones and was not detectable in control
cells (designated as C2C12/Vector). Since clone 1 and 2
displayed similar processes of differentiation, clone 1 (des-
ignated as C2C12/CKLF2) that had the highest expression
level of CKLF2 was further analyzed as the representative
(Fig. 1).
3.2. Morphological changes and differentiation induced by
overexpression of CKLF2 in serum-rich medium
Myoblasts transfected with CKLF2 appeared flat,
enlarged and the spontaneous myotubes were distinct, while
those transfected with the empty vector displayed no such
changes in GM. In order to evaluate the activation of
CKLF2 on myogenesis in serum-rich medium, we cultured
cells continuously in serum-rich medium after they reach
confluence. As is shown in Fig. 2A, when cells were
cultured in serum-rich medium for another 2 days after they
reached confluence, distinct myotube formation was
observed in C2C12/CKLF2 cells, while no such phenomena
except cell elongation and aligning were found in the
control cells. Western blot analysis (Fig. 2B) revealed that
myogenin expression was barely detectable in control
C2C12 myoblasts; in contrast, C2C12/CKLF2 cultures
activated myogenin expression at the myoblast stage. This
likely reflects the increase in differentiation of C2C12 cells
by CKLF2 and we cannot exclude the possibility that
CKLF2 exerts its action by promoting cell proliferation.
3.3. Overexpression of CKLF2 promotes the proliferation of
C2C12 cells
In the normal cultures, we found C2C12/CKLF2
cultures often reached confluence 24 h or more before
the control transfected cells (data not shown). In order to
know if CKLF2 accelerates the differentiation of C2C12s
Fig. 1. Analysis of CKLF2 expression in C2C12 cells. The expression of
CKLF2 was analyzed by semiquantitative RT-PCR from cells that were
transfected with pcDNA3.1–CKLF2 and the vector control.
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by promoting their proliferation or by promoting both pro-
liferation and differentiation of C2C12 cells, we analyzed the
growth curves of C2C12/CKLF2 and C2C12/Vector cells.
After being seeded, the control and CKLF2-transfected
myoblasts maintained in DMEM plus 15% fetal calf serum
were counted at 1, 2, 3, 4 and 5 days. As illustrated in Fig. 3A,
myoblasts expressing CKLF2 grown faster than control cells.
With the equal initial cells, C2C12/CKLF2 cells were almost
three times more than control cells after 4 days culture. These
results indicated that CKLF2 could stimulate the proliferation
of myoblasts. Cell cycle analysis also indicated there was a
significant increase in the number of proliferating cells (G2/
M and S phase) in the C2C12/CKLF2 myoblasts (Fig. 3B).
Consistent with this, CKLF2-stimulated increase in prolifer-
ation, DNA synthesis was also increased in the C2C12/
CKLF2 myoblasts, as evidenced by a greater increase in
[3H]thymidine uptake in these cells compared with control
myoblasts (Fig. 3C).
3.4. Morphological changes and differentiation induced by
overexpression of CKLF2 in DM
Since myotubes appeared in myoblasts transfected with
CKLF2, we examined whether CKLF2 expression in C2C12
cells could also promote cell differentiation in DM. We
stained the cells with FITC-labeled phalloidin and analyzed
the morphological phenotype of control cells as well as
C2C12/CKLF2 cells as they differentiated. As shown in
Fig. 4, expression of CKLF2 accelerated cell differentiation
and generated pronounced myotube hypertrophy. On the
second day of switching to DM, extensive and pronounced
myotubes were observed in C2C12/CKLF2 cells, while few
myotubes were seen in control cells. On the fourth day of
differentiation, muscle hypertrophy was seen in C2C12/
CKLF2 cells, while the myotubes in the control cells were
fewer and thinner.
3.5. Overexpression of CKLF2 promotes the myogenic
differentiation of C2C12 cells
Next, we analyzed how CKLF2 affected the differentia-
tion process of C2C12 cells. Myoblasts were induced to
differentiate in DM with quantitative real-time RT-PCR and
Western blot used to analyze the expression levels of several
muscle-specific genes, such as MLC2, myosin heavy chain
(MHC) and MCK. The expression level of MLC2, MHC and
MCK can represent the differentiation state of cells. The
induction of MLC2 and MCK muscle differentiation marker
molecules by CKLF2 was confirmed by real-time quantita-
tive RT-PCR (Fig. 5A). As shown in Fig. 5A, the expression
of MLC2 and MCK was induced in both cell lines as a result
of their growth in DM. C2C12/CKLF2 cells displayed an
increase of the transcripts in MLC2 andMCK compared with
control cells. The quantitative data is shown in the table in
Fig. 5A. Metabolic evaluation of C2C12 myotubes by crea-
tine kinase assay indicated that creatine kinase activity was
elevated in CKLF2-transfected cells (Fig. 5B). Western blot
of another myogenic marker, MHC, also showed enhanced
and earlier expression in cells expressing CKLF2 (Fig. 5C).
3.6. CKLF2 potentiates the myogenic program by induction
of myogenin expression
In order to uncover the mechanism of CKLF2 promoting
muscle differentiation, we focused on the expression of the
master transcription factor in muscle cells, myogenin. West-
ern blot analysis has shown that CKLF2 could enhance the
expression of myogenin in serum-rich medium (Fig. 2B).
So, we also checked the expression of myogenin in differ-
entiated cells. Cell nuclear extracts at different stages were
prepared and subjected to Western blot. As illustrated in Fig.
6A, CKLF2 could activate the expression of myogenin of
C2C12 cells cultured in DM, which is in agreement with its
stimulating effect on the expression of myogenin of C2C12
cells cultured in GM.
We also checked the transcription of myogenin by a
reporter plasmid. Yee and Rigby [19] have described that a
133-bp myogenin proximal promoter contained sufficient
cis-elements to correctly target a lacZ transgene to specific
muscle-forming regions. Furthermore, an E box, an MEF2
site, and an MEF3 site within this 133-bp proximal myo-
Fig. 2. Myotubes formation of C2C12/CKLF2 cells in serum-rich culture.
C2C12/CKLF2 and the control myoblast cell line were cultured in GM for
an additional 48 h after they reached confluence. (A) Cells were fixed and
myotubes were identified by staining with FITC–phalloidin. (B) C2C12/
CKLF2 and the control myoblasts were harvested for nuclear protein
isolation, and expression of myogenin was detected by Western blot.
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Fig. 3. CKLF2 promotes the proliferation of C2C12 cells. (A) C2C12 cells were plated in six-well plates for triple wells, and the average cell number was
calculated by trypan blue exclusion every day. The time-dependent increase in the number of myoblasts of control and CKLF2-transfected cells is shown
( P< 0.01). At 72 h, there is an approximately three-fold increase in the number of myoblasts transfected with CKLF2 compared with control myoblasts. (B)
C2C12/CKLF2 and control cells were cultured in growth medium to 70% confluence, and cells were harvested, fixed and stained with PI. FCS analysis was
performed on Becton-Dickinson FACScan flow cytometry system. This graph is a representation of three independent analysis. C2C12/CKLF2 is significant
different from control cells ( P < 0.01). (C) [3H]TdR incorporation was determined to evaluate the DNA synthesis. To avoid contract inhibition, we seeded
C2C12/CKLF2 and control cells into 96-well plate at different cell density in 2% FCS DMEM. This graph is a representation of three independent experiments
and C2C12/CKLF2 is significantly different from control cells ( P < 0.01).
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genin promoter have been identified as critical cis-elements
regulating myogenin expression [28–32]. MyoD and MEF2
proteins have been implicated as the nuclear factors binding
these cis-elements. We constructed a myogenin promoter-
Luc reporter plasmid by cloning the fragment containing the
proximal 133 bp upstream of a luciferase gene and checked
the transcription of myogenin. The transcription state of
myogenin can be represented by luciferase activity. From
Fig. 6B, we provided evidence that CKLF2 promoted
myogenin expression by increasing the transcription of
myogenin.
3.7. CKLF2 could activate the transcription activity of
BHLH/myoD family and MEF2 family
The above data provide evidences that CKLF2 potentiates
the myogenic program by induction of myogenin expression.
Are there any other mechanisms involved in this process? In
fact, the induction ofmyogenic differentiation by theMRFs is
achieved by interaction with multiple additional transcription
factors. Among these, the MEF-2 family is involved in a
complex regulatory network with the MRFs [33,34].
From the above results, we can conclude that CKLF2
could promote the transcription of several muscle-specific
molecules such as MCK and myogenin. As previously
reported, E-box and MEF2 box are often in tandem on the
promoter of some muscle-specific genes. Does CKLF2
activate the transcription of MEF2C, the main MEF2 family
member in differentiated muscle, as well as myogenin? To
answer this question, we analyzed the expression of mouse
MEF2C by quantitative RT-PCR. We did not observe that
MEF2C expression was particularly altered in the CKLF2-
expressing cells (data not shown). However, MCK, a known
target of MEF2C, was stimulated to express at a higher level
in C2C12/CKLF2 than in the control C2C12 cultures (Fig.
5A). As we have known, MCK gene promoter contains an
MEF2 binding site, which is essential for its activity in
addition to several MRF E-box targets [34].
Fig. 4. Analysis of morphological changes of C2C12 transfected with
pcDNA3.1–CKLF2. C2C12/CKLF2 cells and the control C2C12 cells
were cultured in DM for 4 days after they reached confluence. Cells were
fixed and myotubes were identified by staining with FITC–phalloidin at
indicated times.
Fig. 5. CKLF2 affects the expression of MLC2, MCK and MHC. (A)
Expression of MLC2 and MCK was determined by real-time PCR. The
cDNA samples from C2C12/CKLF2 and control cells were used in real-
time PCR reactions as described in Materials and methods. The amount of
product for each PCR reaction was calculated from the incorporation of
SYBR green, and 18S rRNA was used as a reference and all molecular
markers were evaluated as to their abundance with respect to 18S rRNA of
that cDNA sample. (B) MCK activities were determined between C2C12/
Vector and C2C12/CKLF2 cells. C2C12/Vector and C2C12/CKLF2 were
cultured and induced to differentiation; cell extracts were prepared at
indicated times. Results are expressed as the relative CK activity (%)
between C2C12/CKLF2 and control cells. CK activity of C2C12/CKLF2 in
Day 3 was arbitrarily set at 100%. The error bar means the maximum
variation of data. C2C12/CKLF2 is significant different from control cells
in Day 3 after induction ( P< 0.01). This graph is a representation of three
independent experiments. (C) Expression of myosin heavy chain at
indicated times was determined by Western blot.
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So, we analyzed the transcription activity profile of
MEF2 and bHLH/MyoD reporter plasmid in C2C12/Vector
and C2C12/CKLF2 cells. We tested the potential of CKLF2
to activate MyoD/bHLH mediated transactivation of an E
box/bHLH factor-dependent reporter, 4RE-tK-Luc, and
MEF2 mediated transactivation of MEF2 factor-dependent
reporter, 3MEF2-tK-Luc. As is expected, we observed
the activation of the E box-dependent reporter and MEF2-
dependent reporter. As is illustrated in Fig. 7, CKLF2
promoted the transcription activity of bHLH/MyoD and
MEF2 simultaneously. And interestingly, the MEF2 reporter
was more responsive to CKLF2 than bHLH/MyoD reporter.
This suggests that the activation of MEF2C gene expression
by CKLF2 reinforces and amplifies its effect on the myo-
genic program.
3.8. CKLF2 acts as a paracrine growth factor
Previous studies have demonstrated that CKLF1 was a
secreted cytokine while CKLF2 was not detected from cell
supernatant in a transient transfection assay [1]. However, in
order to study the paracrine effects of CKLF2, we treated
Fig. 7. CKLF2 activates MEF-2C and bHLH/MyoD-mediated trans-
activation of muscle-specific gene expression. C2C12/CKLF2 and the
control cells were transiently transfected with 4RE-Luc and 3MEF2-Luc
reporter gene and induced to differentiation. Cell extract was prepared at
indicated time and luciferase assay was performed on POLARstar galaxy
luminometer. Fold activation is expressed relative to Luc activity obtained
after transfection the 4RE-Luc and 3MEF2-Luc reporter to the C2C12/
vector cells. Activation mediated by control cells is arbitrarily set at 1. Data
presented are representative of three independent tests. Luciferase activities
in CKLF2-transfected cells are significantly different from those in control
cells ( P< 0.01).
Fig. 8. CKLF2 stimulates cell proliferation and differentiation by paracrine
effects. (A) Wild type C2C12 cells were cultured in 80% CKLF2 or control
conditioned medium for 2 days, and DNA synthesis of different treated
cells was accessed by [3H]TdR incorporation. Student’s t-test was
employed and significant difference exists between the two treated groups
( P < 0.01). (B) Wild C2C12 cells were cultured in exclusively in CKLF2 or
control conditioned medium and switched to conditioned DM when cells
reached confluence. Differentiation was allowed, and cells were harvested
for photography at day 2 after induction.
Fig. 6. CKLF2 promotes the differentiation of C2C12 by enhancing the
expression of myogenin. (A) Cells were cultured in differentiation medium
at indicated times, nuclear proteins were isolated and subjected to Western
blot, 20 Ag protein was loaded in each lane, and the expression of myogenin
was detected with the myogenin-specific antibody (F5D, Pharmingen) (B)
CKLF2 enhanced myogenin promoter activity. C2C12/vector and C2C12/
CKLF2 myoblasts were transiently transfected with a myogenin-Luc vector.
Cell cultures were shifted to differentiation medium 24 h after transfection
and cultured for an additional 48 h. Cell extracts were prepared at myoblast
(day 0), day 1 and day 2 after induction to differentiation. Luciferase is
expressed as relative activity between two groups with control being set at
1. This graph is a representation of three independent experiments, which
demonstrated luciferase activity in CKLF2-transfected cells are signifi-
cantly different from those in control cells ( P < 0.01).
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wild C2C12 myoblasts with the medium harvested from
CKLF2-transfected cells and control conditioned medium.
[3H]TdR incorporation was used to evaluate cell prolifer-
ation. As is shown in Fig. 8A, CKLF2-treated cells showed
enhanced DNA synthesis compared with control. In agree-
ment with our above data, myotube formation and cell
contraction were more distinct in CKLF2-treated cells than
those observed in control-treated cells. As is seen in Fig. 8B,
extensive cell contraction was observed in CKLF2-treated
cells, while extensive cell death existed in control-treated
cells. These paracrine effects suggested that secreted or shed
CKLF2 should exist in the conditioned medium, although
we could not exclude the intracellular function of CKLF2.
These results demonstrate the paracrine role of CKLF2 in
mediating the process of cell proliferation and myotube
differentiation.
4. Discussion
CKLF1 is a novel cytokine having a unique structure and
multiple activities. We have demonstrated that CKLF1 may
participate in a wide range of physiological processes
including stimulating the regeneration of skeletal muscle
cells in vivo. In our last paper, we put forward three possible
mechanisms by which CKLF1 could regulate muscle regen-
eration: firstly, CKLF1 itself has promoting effects on the
proliferation and differentiation of skeletal muscle satellite
cells in the same way as IGF-1; secondly, the leukocytes
attracted by CKLF1 produce different kinds of cytokines
when activated, which influence the growth of myogenic
cells; thirdly, CKLF1 has a synergistic action with some of
the secreted cytokines to increase the rate of cellular pro-
liferation and the formation of myotubes.
To gain insight into the mechanism underlying the
stimulatory effect of CKLF on muscle regeneration in vivo
[1], we focused our analysis on the mouse satellite cell line,
C2C12, in an in vitro transfection assay by investigating the
direct involvement of CKLF in regulation of muscle cell
proliferation and differentiation. Preliminary studies showed
that the rat and mouse homologue of CKLF2 may partic-
ipate in the growth of muscle cells and that murine and
rattus CKLF2 were upregulated accompanied with muscle-
specific molecule markers upon serum-deprivation in mouse
or rat primary satellite cells (data not shown). So, we
established the stable C2C12 cell line that expressed
CKLF2, the largest isoform, under a CMV promoter to
study CKLF2’s activities on the muscle cells.
Our data provide evidences that overexpression of
human CKLF2 in C2C12 cells potentiates and accelerates
the proliferation and myogenic program, inducing dramatic
myotube hypertrophy. This action may be dependent on
the upregulation of myogenin and transactivation of
bHLH/MyoD and MEF2C. MEF2C, the main MEF2
member in differentiated muscle cells, did not show any
particular change of RNA transcripts in C2C12/CKLF2
cells, which is inconsistent with the fold activation of
MEF2 transcription activity. The disparity between MEF2
activity and mRNA levels has been reported previously in
MEF2 family members. Suzuki et al. [35] have reported
that in vascular smooth muscle cells, MEF2A protein
levels dramatically increase in response to serum stimula-
tion, without a corresponding change in mRNA levels.
Previous researches have demonstrated that various signal-
ing systems are implicated in the control of MEF2 activity.
Several cofactors including members of bHLH family have
been identified to modulate the activity of MEF2 by
protein interaction. For example, bHLH factors, pRb [36]
and p300 [37] could stimulate the activity of MEF2 by
physical interaction; MITR [38], Twist [39] and HDAC
[40] factors act as inhibitory cofactors. Mitogen-activated
protein kinases play a pivotal role in regulation of MEF2
activity by protein phosphorylation and the calcium/calm-
odulin-dependent phosphatase, calcineurin, stimulates
MEF2 transcriptional activity by inducing a cofactor or a
posttranslational modification of MEF2 that potentiates
transcriptional activity [41–46]. Therefore, we postulate
that CKLF2 could activate MEF2 through other mecha-
nisms that exclude RNA transcription. Further analysis will
answer this question and elucidate these mechanisms and
signaling pathway.
Although previous studies did not detect CKLF2 in
supernatant by Western blot, this study determines the
paracrine effects of CKLF2, it suggests CKLF2 acts as a
paracrine growth factor in this system. We also have cloned
the mouse and rat homologue of CKLF2 simultaneously,
and found both rat CKLF2 and mouse CKLF2 contained a
CX3C motif in their C-terminal regions [unpublished data]
while human CKLFs contained a CC motif in the same
region. So, we postulate CKLFs are bridge molecules
between CC chemokines and CX3C chemokines. Tsou et
al. [47] have reported tumor necrosis factor-converting
enzyme (TACE) could cleave the membrane-bound fractal-
kine, the only member of CX3C chemokine, and result in a
soluble form of fractalkine that is also a potent chemo-
attractant for lymphocyte cells. Therefore, we postulated
that CKLF2 could be processed into the soluble form. Also,
Uruno et al. [48] reported distinct regulation of myogenic
differentiation by intracellular and extracellular FGF-1
(aFGF). They found that endogenous FGF-1 did not sup-
press myoblast differentiation while FGF-1 protein in cul-
ture medium suppressed it. So, we could not exclude some
regulation of the intracellular function of CKLF2. Further
studies are underway to elucidate this mechanism.
From our previous data, we hypothesized a role for
CKLF2 in the establishment and maintenance of the mature
muscle phenotype in normal and regenerating muscle tissue.
From this paper, we can conclude that CKLF2 may exert
double effects on the mouse satellite cell line, C2C12. With
its proliferation-promoting effect on the growing cells and
its myogenic-promoting effect on the postmitotic cells,
CKLF2 is another protein, which has a double action on
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muscle cells, besides IGF-1 [27,49,50]. The pleiotropic
actions of CKLF2 in normal muscle growth and regener-
ation suggest a crucial role for this protein in multiple steps
of the myogenic program. We purpose that in injured
muscle, just like IGF-1 [51], CKLF2 is transiently induced
to stimulate the proliferation of quiescent satellite cells to
enter the cell cycle and to promote the differentiation of
satellite cells when they reach confluence. Subsequent
studies also have indicated similar stimulatory effects of
mouse CKLF2 on C2C12 cells. This indicates that the
enhancing effect of CKLF2 on the muscle regeneration
may be evolutionarily conserved.
In summary, we have demonstrated that CKLF2 could
stimulate the proliferation and differentiation of C2C12
skeletal muscle cells. So, CKLF2 may play a pivotal role
in regulation of development and regeneration of skeletal
muscle. As we have known, many growth factors including
FGF and HGF are required for migration, proliferation and
differentiation of embryonic myogenic precursor cells.
CKLF2 may be one of such factors. So, extensive studies
on CKLF2 function on skeletal muscle will be helpful in
uncovering the operating mechanisms and networks con-
trolling the development and regeneration of skeletal
muscle.
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